Drug may shield kidneys from dye harm in ICU
NCT ID NCT07561801
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether pentoxifylline, a drug that improves blood flow, can prevent kidney damage caused by contrast dye used in medical imaging. The trial included 70 adults with chronic kidney disease who were in the intensive care unit and needed contrast dye. Researchers measured how many patients developed contrast-induced nephropathy, changes in kidney function, length of ICU stay, and need for dialysis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONTRAST-INDUCED NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tanta University
Tanta, El-Gharbia, 31527, Egypt